Randomized Trial of a Biodegradable Polymer Stent

Data at 1 year show promise for a biolimus-eluting stent.

Biodegradable polymers and stents represent the next development frontier of coronary stent technology. In a trial conducted at 98 hospitals in Japan, researchers randomized 3235 patients undergoing percutaneous coronary intervention (PCI) to receive either a biolimus-eluting stent (BES), made of stainless steel and a biodegradable polymer, or the most commonly used stent in the U.S., an everolimus-eluting stent (EES) made of cobalt-chromium with a durable polymer. The manufacturer of the BES (brand name Nobori) funded the study. Xience and Promus are the widely known brands of EES.

The procedural success rate was 97% in both groups, and 1-year follow-up was obtained in >99% of patients. The incidence of target-lesion revascularization at 1 …

Reviewing Author

Howard C. Herrmann, MD

Disclosures

Consultant/Advisory BoardAffluent Medical; Artedrone; Caranx; Johnson & Johnson; Medtronic; Prolifagen; Wells Fargo

EquityMicrointerventional Devices, Inc.

RoyaltiesUniversity of Pennsylvania

Grant/Research SupportAbbott Vascular; Edwards Lifesciences; Johnson & Johnson; Medtronic

Editorial BoardsCatheterization and Cardiovascular Interventions; Journal of the American College of Cardiology; Circulation: Cardiovascular Interventions; JACC Cardiovascular Interventions; JACC Case Reports; JSCAI

Leadership Positions in Professional SocietiesHeart Valve Collaboratory (Scientific Committee Member, Chair of the Publications Committee)